健脾补肾解毒方调控JAK2/STAT3通路对肝癌细胞增殖与迁移的影响

扫码查看

原文链接

万方数据

中文摘要：目的研究健脾补肾解毒方对肝癌细胞增殖、迁移的影响，探讨其作用机制。方法以人高转移肝癌细胞株（HCCLM3）为研究对象，将其按随机数字表法分为对照组、中药组（100、200、400、800、1 600、3 200 μg/ml健脾补肾解毒方）及西药组（2.5、5、10、20、40 μmol/L索拉非尼），采用胞计数试剂（CCK-8）法检测细胞活力；将HCCLM3细胞按随机数字表法分为中药低、中、高剂量组（健脾补肾解毒方醇提液100、800、1 600 μg/ml）、西药组（索拉非尼20 μmol/L）及对照组，采用划痕实验检测HCCLM3迁移情况。将HCCLM3细胞按随机数字表法分为对照组、中药组（健脾补肾解毒方800 μg/ml）和联合组（健脾补肾解毒方800 μg/ml+索拉非尼20 μmol/L），采用Western blot法检测各组细胞蛋白激酶/信号传导子和转录激活子（JAK2/STAT3）通路相关蛋白（p-JAK2、JAK2、p-STAT3、STAT3）表达情况。结果与对照组比较，中药组及西药组HCCLM细胞活力及迁移率降低（P<0.01或P<0.05）；与对照组比较，中药组、联合组P-JAK2、JAK2、p-STAT3、STAT3蛋白表达降低（P<0.05），且联合组JAK2蛋白表达低于中药组（P<0.05）。结论健脾补肾解毒方通过调控JAK2/STAT3通路对肝癌细胞的增殖与迁移产生抑制作用。 Objective To explore the effects of Jianpi Bushen Jiedu Prescription on the proliferation and migration of hepatocellular carcinoma cells To discuss its possible mechanism. Methods Using human highly metastatic liver cancer cell line (HCCLM3) as the research object, they were randomly divided into control group and TCM group (100, 200, 400, 800, 1 600, 3 200 μg/ml Jianpi Bushen Jiedu Prescription) and Western medicine group (2.5, 5, 10, 20, 40 μmol/L sorafenib) using a random number table method. Cell viability was detected using cell counting reagent (CCK-8) method HCCLM3 cells were divided into control group and TCM (Jianpi Bushen Jiedu Prescription 800 μg/ml) group and combined group (Jianpi Bushen Jiedu Prescription 800 μg/ml +sorafenib 20 μmol/L). Western blot method was used to detect the protein expressions of kinase/signaling transducer and transcriptional activator (JAK2/STAT3) pathway related proteins (p-JAK2, JAK2, p-STAT3, STAT3) in each group. Results Compared with the control group, viability and mobility of HCCLM cell in TCM group and Western medicine group decreased (P<0.01 orP<0.05) compared with the control group, the protein expressions of P-JAK2, JAK2, P-STAT3 and STAT3 in the TCM group and the combined group decreased (P<0.05), and the JAK2 protein expression in the combined group was lower than that in the TCM group (P<0.05). Conclusion Jianpi Bushen Jiedu Prescription can inhibit the proliferation and migration of HCC cells by regulating JAK2/STAT3 pathway.

外文标题：Effects of Jianpi Bushen Jiedu Prescription regulating JAK2/STAT3 pathway on proliferation and migration of hepatocellular carcinoma cells

外文摘要：Objective To explore the effects of Jianpi Bushen Jiedu Prescription on the proliferation and migration of hepatocellular carcinoma cells To discuss its possible mechanism. Methods Using human highly metastatic liver cancer cell line (HCCLM3) as the research object, they were randomly divided into control group and TCM group (100, 200, 400, 800, 1 600, 3 200 μg/ml Jianpi Bushen Jiedu Prescription) and Western medicine group (2.5, 5, 10, 20, 40 μmol/L sorafenib) using a random number table method. Cell viability was detected using cell counting reagent (CCK-8) method HCCLM3 cells were divided into control group and TCM (Jianpi Bushen Jiedu Prescription 800 μg/ml) group and combined group (Jianpi Bushen Jiedu Prescription 800 μg/ml +sorafenib 20 μmol/L). Western blot method was used to detect the protein expressions of kinase/signaling transducer and transcriptional activator (JAK2/STAT3) pathway related proteins (p-JAK2, JAK2, p-STAT3, STAT3) in each group. Results Compared with the control group, viability and mobility of HCCLM cell in TCM group and Western medicine group decreased (P<0.01 orP<0.05) compared with the control group, the protein expressions of P-JAK2, JAK2, P-STAT3 and STAT3 in the TCM group and the combined group decreased (P<0.05), and the JAK2 protein expression in the combined group was lower than that in the TCM group (P<0.05). Conclusion Jianpi Bushen Jiedu Prescription can inhibit the proliferation and migration of HCC cells by regulating JAK2/STAT3 pathway.

外文关键词：

Liver neoplasmsSpleen-tonifying kidney detoxification prescriptionJAK2/STAT3 pathwayCell proliferationCell migration

作者：

李会娣、冯媛媛、赖优莹、贾茹、张平平、朱晓骏、刘宏杰、张琪

展开 >

作者单位：

上海中医药大学附属曙光医院肿瘤科，上海　201203

上海中医药大学附属曙光医院肝病科，上海　201203

关键词：

肝肿瘤健脾补肾解毒方 JAK2/STAT3通路细胞增殖细胞迁移

基金：

国家自然科学基金上海市中医药三年行动计划(2021-2023)项目上海市炎癌转化病症生物学前沿研究基地项目上海中医药大学预算内课题

项目编号：

81774256ZY2021-2023-02082021KJ03-122019LK011

出版年：

2024

DOI：

10.3760/cma.j.cn115398-20221226-00344

国际中医中药杂志

中华医学会,中国中医科学院中医药信息研究所

国际中医中药杂志

CSTPCD

影响因子：0.411

ISSN：1673-4246

年,卷(期)：2024.46(2)

参考文献量21